Panacea Biotec shares hit 5% upper circuit after securing Rs 127 crore vaccine supply contract from UNICEF

Panacea Biotec Ltd has surged to its 5% upper circuit, trading at ₹454.90, following the announcement of a significant Letter of Award from UNICEF. The company has been entrusted with the supply of 115 million doses of its bivalent oral polio vaccine (bOPV) for the calendar year 2025.

Key Highlights:

• Order Details: Supply of 115 million doses of bOPV to UNICEF for its vaccination programs across Africa and Asia.
• Contract Value: Approx. $14.95 million (~₹127 crore).
• Execution Period: Calendar year 2025.
• Scope: Strengthening global immunization programs in critical regions.

Strategic Importance:

This international contract highlights Panacea Biotec’s capabilities in manufacturing high-quality vaccines for large-scale requirements. It not only boosts the company’s international revenue stream but also reinforces its reputation as a significant contributor to global healthcare initiatives.

Stock Performance:

• Opening Price: ₹454.90
• Day’s High: ₹454.90
• Previous Close: ₹433.25

Panacea Biotec Share Price history